Clara D Bloomfield MD


Clara D Bloomfield MD
ProfessorCollege of Medicinebloomfield.28@osu.edu
1216 James Cancer Hosp & Res Inst 300 W 10th Avenue Columbus Ohio 43210
Phone:614-293-7518Fax: 614-366-1637
  • Molecular Biology and Cancer Genetics

Research Description

After serving as director of the OSU Comprehensive Cancer Center from 1997 to July 2003, Dr. Bloomfield became Senior Advisor to the OSU cancer program and the charter member of the OSU Cancer Scholars Program, which is designed to help recruit and retain senior cancer investigators of international stature. Bloomfield is renowned for her more than three decades of research in adult leukemia and lymphoma, research that has been described in more than 600 publications and which has helped change standards of treatment. Bloomfield earned her MD from the University of Chicago and completed training in internal medicine and medical oncology at the University of Minnesota, where she became a full professor in seven years. In 1989 she became professor of medicine and chief of the Division of Oncology at the State University of New York at Buffalo, as well as chair of the Division of Medicine at Roswell Park Cancer Institute. She came to Ohio State in 1997, and in 2000 she was elected to the Institute of Medicine of the National Academy of Sciences. At the OSUCCC, she serves as cancer scholar and senior adviser. She is also a member of the Molecular Biology and Cancer Genetics Program, a professor of internal medicine and holder of the William Greenville Pace III Endowed Chair in Cancer Research.

Current Publications

  • de la Chapelle AIntronic miR-3151 Within BAALC Drives Leukemogenesis by Deregulating the TP53 Pathway.Sci Signal 7 ra36 4/15/2014
  • Garzon RImplications of the miR-10 family in chemotherapy response of NPM1-mutated AML.Blood 123 2412-5 4/10/2014
  • Hoster ECombined Molecular and Clinical Prognostic Index for Relapse and Survival in Cytogenetically Normal Acute Myeloid Leukemia.J Clin Oncol 4/7/2014
  • Marcucci GSPARC promotes leukemic cell growth and predicts acute myeloid leukemia outcome.J Clin Invest 124 1512-24 4/1/2014
  • Larson RARecombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: Results from Cancer and Leukemia Group B 19808.Cancer 120 1010-7 4/1/2014
  • Bloomfield CDGeoffrey Peter Herzig, MD Leukemia Pioneer (1941-2013).Leukemia 3/21/2014
  • Bloomfield CDPrognostic gene mutations and distinct gene- and microRNA-expression signatures in acute myeloid leukemia with a sole trisomy 8.Leukemia 3/21/2014
  • de la Chapelle ANRAS isoforms differentially affect downstream pathways, cell growth, and cell transformation.Proc Natl Acad Sci U S A 111 4179-84 3/18/2014
  • Bloomfield CDEpigenetics meets genetics in acute myeloid leukemia: clinical impact of a novel seven-gene score.J Clin Oncol 32 548-56 2/20/2014
  • Poiré X, Moser BK, Gallagher RE, Laumann K, Bloomfield CD, Powell BL, Koval G, Gulati K, Holowka N, Larson RA, Tallman MS, Appelbaum FR, Sher D, Willman C, Paietta E, Stock WArsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype.Leuk Lymphoma 2/4/2014
  • Bloomfield CDReply to "Rare coincident NPM1 and RUNX1 mutations in intermediate risk acute myeloid leukemia display similar patterns to single mutated cases". Haematologica 2014;99(2):e20-21.Haematologica 99 e22 2/1/2014
  • Bloomfield CDIntensive induction is effective in selected octogenarian acute myeloid leukemia patients: prognostic significance of karyotype and selected molecular markers used in the European LeukemiaNet classification.Haematologica 99 308-13 2/1/2014
  • Larson RAAutologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: results of CALGB Study 10001 (Alliance).Haematologica 99 111-5 1/1/2014
  • Bloomfield CDGAS6 expression identifies high-risk adult AML patients: potential implications for therapy.Leukemia 12/11/2013
  • Woods WG, Franklin AR, Alonzo TA, Gerbing RB, Donohue KA, Othus M, Horan J, Appelbaum FR, Estey EH, Bloomfield CD, Larson RAOutcome of adolescents and young adults with acute myeloid leukemia treated on COG trials compared to CALGB and SWOG trials.Cancer 119 4170-9 12/1/2013
  • Goldberg L, Tijssen MR, Birger Y, Hannah RL, Kinston SJ, Schütte J, Beck D, Knezevic K, Schiby G, Jacob-Hirsch J, Biran A, Kloog Y, Marcucci G, Bloomfield CD, Aplan PD, Pimanda JE, Göttgens B, Izraeli SGenome-scale expression and transcription factor binding profiles reveal therapeutic targets in transgenic ERG myeloid leukemia.Blood 122(15) 2694-703 10/10/2013
  • Metzeler KH, Maharry K, Kohlschmidt J, Volinia S, Mrózek K, Becker H, Nicolet D, Whitman SP, Mendler JH, Schwind S, Eisfeld AK, Wu YZ, Powell BL, Carter TH, Wetzler M, Kolitz JE, Baer MR, Carroll AJ, Stone RM, Caligiuri MA, Marcucci G, Bloomfield CDA stem cell-like gene expression signature associates with inferior outcomes and a distinct microRNA expression profile in adults with primary cytogenetically normal acute myeloid leukemia.Leukemia 27(10) 2023-31 10/1/2013
  • Gupta P, Mulkey F, Hasserjian RP, Sanford BL, Vij R, Hurd DD, Odenike OM, Bloomfield CD, Owzar K, Stone RM, Larson RAA phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance).Invest New Drugs 31(5) 1311-20 10/1/2013
  • Bloomfield CDIn rare acute myeloid leukemia patients harboring both RUNX1 and NPM1 mutations, RUNX1 mutations are unusual in structure and present in the germline.Haematologica 98(8) e92-4 8/1/2013
  • Katz ML, Ferketich AK, Paskett ED, Bloomfield CDHealth literacy among the Amish: measuring a complex concept among a unique population.J Community Health 38(4) 753-8 8/1/2013
  • Douer D, Zickl LN, Schiffer CA, Appelbaum FR, Feusner JH, Shepherd L, Willman CL, Bloomfield CD, Paietta E, Gallagher RE, Park JH, Rowe JM, Wiernik PH, Tallman MSAll-trans retinoic acid and late relapses in acute promyelocytic leukemia: very long-term follow-up of the North American Intergroup Study I0129.Leuk Res 37(7) 795-801 7/1/2013
  • Greenberg PL, Attar E, Bennett JM, Bloomfield CD, Borate U, De Castro CM, Deeg HJ, Frankfurt O, Gaensler K, Garcia-Manero G, Gore SD, Head D, Komrokji R, Maness LJ, Millenson M, O'Donnell MR, Shami PJ, Stein BL, Stone RM, Thompson JE, Westervelt P, Wheeler B, Shead DA, Naganuma MMyelodysplastic syndromes: clinical practice guidelines in oncology.J Natl Compr Canc Netw 11(7) 838-74 7/1/2013
  • Mrózek K, Nicolet D, Maharry KS, Carroll AJ, Marcucci G, Bloomfield CDReply to K. Orendi et al.J Clin Oncol 31(18) 2361-2 6/20/2013
  • Marcucci G, Maharry KS, Metzeler KH, Volinia S, Wu YZ, Mrózek K, Nicolet D, Kohlschmidt J, Whitman SP, Mendler JH, Schwind S, Becker H, Eisfeld AK, Carroll AJ, Powell BL, Kolitz JE, Garzon R, Caligiuri MA, Stone RM, Bloomfield CDClinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients.J Clin Oncol 31(17) 2086-93 6/10/2013
  • Huang X, Schwind S, Yu B, Santhanam R, Wang H, Hoellerbauer P, Mims A, Klisovic RB, Walker A, Chan KK, Blum W, Perrotti D, Byrd JC, Bloomfield CD, Caligiuri MA, Lee RJ, Garzon R, Muthusamy N, Lee LJ, Marcucci GTargeted delivery of microRNA-29b by transferrin-conjugated anionic lipopolyplex nanoparticles: a novel therapeutic strategy in acute myeloid leukemia.Clin Cancer Res 19(9) 2355-67 5/1/2013
  • Walker A, Mrózek K, Kohlschmidt J, Rao KW, Pettenati MJ, Sterling LJ, Marcucci G, Carroll AJ, Bloomfield CDNew recurrent balanced translocations in acute myeloid leukemia and myelodysplastic syndromes: cancer and leukemia group B 8461.Genes Chromosomes Cancer 52(4) 385-401 4/1/2013
  • Mims A, Walker AR, Huang X, Sun J, Wang H, Santhanam R, Dorrance AM, Walker C, Hoellerbauer P, Tarighat SS, Chan KK, Klisovic RB, Perrotti D, Caligiuri MA, Byrd JC, Chen CS, Lee LJ, Jacob S, Mrózek K, Bloomfield CD, Blum W, Garzon R, Schwind S, Marcucci GIncreased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemia.Leukemia 27(4) 871-8 4/1/2013
  • Li Z, Herold T, He C, Valk PJ, Chen P, Jurinovic V, Mansmann U, Radmacher MD, Maharry KS, Sun M, Yang X, Huang H, Jiang X, Sauerland MC, Büchner T, Hiddemann W, Elkahloun A, Neilly MB, Zhang Y, Larson RA, Le Beau MM, Caligiuri MA, Döhner K, Bullinger L, Liu PP, Delwel R, Marcucci G, Lowenberg B, Bloomfield CD, Rowley JD, Bohlander SK, Chen JIdentification of a 24-gene prognostic signature that improves the European LeukemiaNet risk classification of acute myeloid leukemia: an international collaborative study.J Clin Oncol 31(9) 1172-81 3/20/2013
  • Attar EC, Johnson JL, Amrein PC, Lozanski G, Wadleigh M, Deangelo DJ, Kolitz JE, Powell BL, Voorhees P, Wang ES, Blum W, Stone RM, Marcucci G, Bloomfield CD, Moser B, Larson RABortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502.J Clin Oncol 31(7) 923-9 3/1/2013
  • Becker H, Bloomfield CDAcute myeloid leukaemia in 2012: En route to improved treatment options.Nat Rev Clin Oncol 10(2) 76-9 2/1/2013
  • Li Y, Gao L, Luo X, Wang L, Gao X, Wang W, Sun J, Dou L, Li J, Xu C, Wang L, Zhou M, Jiang M, Zhou J, Caligiuri MA, Nervi C, Bloomfield CD, Marcucci G, Yu LEpigenetic silencing of microRNA-193a contributes to leukemogenesis in t(8;21) acute myeloid leukemia by activating the PTEN/PI3K signal pathway.Blood 121(3) 499-509 1/17/2013
  • Schwind S, Edwards CG, Nicolet D, Mrózek K, Maharry K, Wu YZ, Paschka P, Eisfeld AK, Hoellerbauer P, Becker H, Metzeler KH, Curfman J, Kohlschmidt J, Prior TW, Kolitz JE, Blum W, Pettenati MJ, Dal Cin P, Carroll AJ, Caligiuri MA, Larson RA, Volinia S, Marcucci G, Bloomfield CDinv(16)/t(16;16) acute myeloid leukemia with non-type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations.Blood 121(2) 385-91 1/10/2013
  • Hickey CJ, Schwind S, Radomska HS, Dorrance AM, Santhanam R, Mishra A, Wu YZ, Alachkar H, Maharry K, Nicolet D, Mrózek K, Walker A, Eiring AM, Whitman SP, Becker H, Perrotti D, Wu LC, Zhao X, Fehniger TA, Vij R, Byrd JC, Blum W, Lee LJ, Caligiuri MA, Bloomfield CD, Garzon R, Marcucci GLenalidomide-mediated enhanced translation of C/EBPα-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia.Blood 121(1) 159-69 1/3/2013
  • Stock W, Johnson JL, Stone RM, Kolitz JE, Powell BL, Wetzler M, Westervelt P, Marcucci G, Deangelo DJ, Vardiman JW, McDonnell D, Mrózek K, Bloomfield CD, Larson RADose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802.Cancer 119(1) 90-8 1/1/2013
  • Mrózek K, Marcucci G, Nicolet D, Maharry KS, Becker H, Whitman SP, Metzeler KH, Schwind S, Wu YZ, Kohlschmidt J, Pettenati MJ, Heerema NA, Block AW, Patil SR, Baer MR, Kolitz JE, Moore JO, Carroll AJ, Stone RM, Larson RA, Bloomfield CDPrognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia.J Clin Oncol 30(36) 4515-23 12/20/2012
  • Yan P, Frankhouser D, Murphy M, Tam HH, Rodriguez B, Curfman J, Trimarchi M, Geyer S, Wu YZ, Whitman SP, Metzeler K, Walker A, Klisovic R, Jacob S, Grever MR, Byrd JC, Bloomfield CD, Garzon R, Blum W, Caligiuri MA, Bundschuh R, Marcucci GGenome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia.Blood 120(12) 2466-74 9/20/2012
  • Gallagher RE, Moser BK, Racevskis J, Poiré X, Bloomfield CD, Carroll AJ, Ketterling RP, Roulston D, Schachter-Tokarz E, Zhou DC, Chen IM, Harvey R, Koval G, Sher DA, Feusner JH, Tallman MS, Larson RA, Powell BL, Appelbaum FR, Paietta E, Willman CL, Stock WTreatment-influenced associations of PML-RARα mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia.Blood 120(10) 2098-108 9/6/2012
  • Mendler JH, Maharry K, Radmacher MD, Mrózek K, Becker H, Metzeler KH, Schwind S, Whitman SP, Khalife J, Kohlschmidt J, Nicolet D, Powell BL, Carter TH, Wetzler M, Moore JO, Kolitz JE, Baer MR, Carroll AJ, Larson RA, Caligiuri MA, Marcucci G, Bloomfield CDRUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures.J Clin Oncol 30(25) 3109-18 9/1/2012
  • Mrózek K, Bloomfield CDAcute myeloid leukemia with adverse cytogenetic risk.Oncology (Williston Park) 26(8) 714, 723 8/1/2012
  • Shlush LI, Chapal-Ilani N, Adar R, Pery N, Maruvka Y, Spiro A, Shouval R, Rowe JM, Tzukerman M, Bercovich D, Izraeli S, Marcucci G, Bloomfield CD, Zuckerman T, Skorecki K, Shapiro ECell lineage analysis of acute leukemia relapse uncovers the role of replication-rate heterogeneity and microsatellite instability.Blood 120(3) 603-12 7/19/2012
  • Eisfeld AK, Marcucci G, Maharry K, Schwind S, Radmacher MD, Nicolet D, Becker H, Mrózek K, Whitman SP, Metzeler KH, Mendler JH, Wu YZ, Liyanarachchi S, Patel R, Baer MR, Powell BL, Carter TH, Moore JO, Kolitz JE, Wetzler M, Caligiuri MA, Larson RA, Tanner SM, de la Chapelle A, Bloomfield CDmiR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia.Blood 120(2) 249-58 7/12/2012
  • Whitman SP, Caligiuri MA, Maharry K, Radmacher MD, Kohlschmidt J, Becker H, Mrózek K, Wu YZ, Schwind S, Metzeler KH, Mendler JH, Wen J, Baer MR, Powell BL, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, Larson RA, Marcucci G, Bloomfield CDThe MLL partial tandem duplication in adults aged 60 years and older with de novo cytogenetically normal acute myeloid leukemia.Leukemia 26(7) 1713-7 7/1/2012
  • Blum W, Schwind S, Tarighat SS, Geyer S, Eisfeld AK, Whitman S, Walker A, Klisovic R, Byrd JC, Santhanam R, Wang H, Curfman JP, Devine SM, Jacob S, Garr C, Kefauver C, Perrotti D, Chan KK, Bloomfield CD, Caligiuri MA, Grever MR, Garzon R, Marcucci GClinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia.Blood 119(25) 6025-31 6/21/2012
  • Metzeler KH, Walker A, Geyer S, Garzon R, Klisovic RB, Bloomfield CD, Blum W, Marcucci GDNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia.Leukemia 26(5) 1106-7 5/1/2012

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu